PD-1 and PD-L1 inhibitors (such as Nivolumab, Pembrolizumab, and Atezolizumab) block the interaction between PD-1 and PD-L1, disrupting this negative regulatory mechanism and reactivating T cell immune responses against tumour cells. Here, CD274 is linked to neoplasm.